Enliven Therapeutics, Inc.
ELVNNASDAQHealthcare● Active
$33.70
$-1.02(-2.92%)
Market Cap$2.1B
P/E Ratio—
52W High$48.53
52W Low$14.785
Enliven Therapeutics, Inc. (ELVN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ELVN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.38
Est. -$0.44 · +13.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ELVN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.41 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.44 | -$0.38 | +13.6% | — | — | — |
| ▼ Q1 FY2026 | Mar 3, 2026 | -$0.42 | -$0.48 | -14.3% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.43 | -$0.32 | +25.6% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.53 | -$0.49 | +7.5% | — | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.51 | -$0.57 | -11.8% | — | — | — |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.53 | -$0.46 | +13.2% | — | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.52 | -$0.48 | +7.7% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.41
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.38
EPS Est.
-$0.44
EPS Surpr.
+13.6%
Revenue
—
Q1 FY2026
Mar 3, 2026Miss
EPS Actual
-$0.48
EPS Est.
-$0.42
EPS Surpr.
-14.3%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.43
EPS Surpr.
+25.6%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.49
EPS Est.
-$0.53
EPS Surpr.
+7.5%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.57
EPS Est.
-$0.51
EPS Surpr.
-11.8%
Revenue
—
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.46
EPS Est.
-$0.53
EPS Surpr.
+13.2%
Revenue
—
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.48
EPS Est.
-$0.52
EPS Surpr.
+7.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q3 FY2027 | $-0.67 | $-0.67 | $-0.67 | 1 |
| Q2 FY2027 | $-0.61 | $-0.61 | $-0.61 | 1 |
| Q1 FY2027 | $-0.54 | $-0.54 | $-0.54 | 1 |
| Q4 FY2026 | $-0.53 | $-0.53 | $-0.53 | 1 |
| Q3 FY2026 | $-0.45 | $-0.45 | $-0.45 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +13.6% | $41.20 | $40.29 | -2.21% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -14.3% | $29.50 | $28.75 | -2.54% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +25.6% | $19.64 | $20.30 | +3.36% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +7.5% | $18.89 | $19.99 | +5.82% |
| ▼ Q2 FY2025 | May 14, 2025 | -11.8% | $20.03 | $19.89 | -0.70% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +13.2% | $21.02 | $20.29 | -3.47% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +7.7% | $27.17 | $25.80 | -5.04% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +29.3% | $21.32 | $21.52 | +0.94% |
Q2 FY2026-2.21%
Report Date
May 7, 2026
EPS Beat/Miss
+13.6%
Price Before
$41.20
Price After
$40.29
Q1 FY2026-2.54%
Report Date
Mar 3, 2026
EPS Beat/Miss
-14.3%
Price Before
$29.50
Price After
$28.75
Q4 FY2025+3.36%
Report Date
Nov 12, 2025
EPS Beat/Miss
+25.6%
Price Before
$19.64
Price After
$20.30
Q3 FY2025+5.82%
Report Date
Aug 13, 2025
EPS Beat/Miss
+7.5%
Price Before
$18.89
Price After
$19.99
Q2 FY2025-0.70%
Report Date
May 14, 2025
EPS Beat/Miss
-11.8%
Price Before
$20.03
Price After
$19.89
Q1 FY2025-3.47%
Report Date
Mar 13, 2025
EPS Beat/Miss
+13.2%
Price Before
$21.02
Price After
$20.29
Q4 FY2024-5.04%
Report Date
Nov 13, 2024
EPS Beat/Miss
+7.7%
Price Before
$27.17
Price After
$25.80
Q3 FY2024+0.94%
Report Date
Aug 13, 2024
EPS Beat/Miss
+29.3%
Price Before
$21.32
Price After
$21.52
Avg Beat Reaction-0.10%
Avg Miss Reaction-1.62%
Beat Rate6 / 8 quarters
Largest Move+5.82% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ELVN ends December
Enliven Therapeutics, Inc. (ELVN) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.38 — beating the analyst consensus of $-0.44 by +13.6%. The next ELVN earnings date is expected around September 1, 2026.
Each quarter, investors track ELVN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ELVN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ELVN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ELVN earnings · 5 questionsEnliven Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ELVN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ELVN historically reports after market close (AMC).
ELVN earnings datewhen is ELVN earningsELVN next earnings datewhen does ELVN report earningsELVN earnings calendar
▸ Source: FMP · Enliven Therapeutics, Inc. SEC filings · US GAAP · Enliven Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026